CNS Pharmaceuticals Statistics
Total Valuation
CNSP has a market cap or net worth of $1.47 million. The enterprise value is -$5.45 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNSP has 1.15 million shares outstanding.
| Current Share Class | 1.15M |
| Shares Outstanding | 1.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 6.15% |
| Float | 1.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.82 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,052.64 |
Financial Efficiency
Return on equity (ROE) is -2,116.75% and return on invested capital (ROIC) is -1,267.40%.
| Return on Equity (ROE) | -2,116.75% |
| Return on Assets (ROA) | -219.28% |
| Return on Invested Capital (ROIC) | -1,267.40% |
| Return on Capital Employed (ROCE) | -509.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.41M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.86% in the last 52 weeks. The beta is 1.12, so CNSP's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -99.86% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 18.05 |
| Relative Strength Index (RSI) | 29.72 |
| Average Volume (20 Days) | 322,277 |
Short Selling Information
The latest short interest is 180,064, so 15.66% of the outstanding shares have been sold short.
| Short Interest | 180,064 |
| Short Previous Month | 268,524 |
| Short % of Shares Out | 15.66% |
| Short % of Float | 15.97% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.08M |
| Pretax Income | -17.46M |
| Net Income | -17.06M |
| EBITDA | -17.08M |
| EBIT | -17.08M |
| Earnings Per Share (EPS) | -$149.32 |
Full Income StatementBalance Sheet
The company has $6.97 million in cash and $31,187 in debt, giving a net cash position of $6.94 million or $6.04 per share.
| Cash & Cash Equivalents | 6.97M |
| Total Debt | 31,187 |
| Net Cash | 6.94M |
| Net Cash Per Share | $6.04 |
| Equity (Book Value) | 3.35M |
| Book Value Per Share | 5.01 |
| Working Capital | 3.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.18 million and capital expenditures -$2,157, giving a free cash flow of -$14.18 million.
| Operating Cash Flow | -14.18M |
| Capital Expenditures | -2,157 |
| Free Cash Flow | -14.18M |
| FCF Per Share | -$12.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |